

Comparison of patient's profile initiating anticytokines and JAK inhibitors for atopic dermatitis in the OMCCI cohort


Anne-Claire Fougousse, Jean-Luc Perrot, Ziad Reguiai, Edouard Begon, Laure Mery Bossard, Domitille Thomas Beaulieu, Diane Pourchot, Antoine Badaoui, Claire Boulard, Charlotte Fite, Ines Zaraa, Dominique Lons Danic, Jessica Beaziz, Josiane Parier, Guillaume Chaby, Anne Laure Liegeon, Alexandra Patchinsky, Axelle Bonhomme, Helene Martin, Amelie Schoeffler, Philippe Muller, Claire Poreaux, Caroline Jacobzone, Kevin Chassain, Claire-Alice De Salins, Jean-Benoît Monfort, Eric Estève, François Maccari, Pierre-André Becherel, for the OMCCI Group

Disclosures


- Anne-Claire Fougèrouse: speaker, consultant or investigator for Abbvie, Sanofi, Leo-Pharma, Lilly, Pfizer
- Institutionnal support of Novartis, Sanofi, Lilly, Leo Pharma, Janssen, UCB Pharma, Almirall



OMCCI Cohort

- French prospective real-world multicenter study of chronic inflammatory skin diseases (atopic dermatitis (AD), psoriasis, hidradenitis suppurativa and chronic spontaneous urticaria)
 - Objective: to determine and compare the impacts of these conditions on sufferer's lives and therapeutic decisions (follow up 4 years)
 - Inclusions started on December 2020 and are ongoing (1810 patients on 8th of June 2022)
- 

Introduction/ Material and Methods

- Therapeutics options for moderate to severe AD in France on June 2022 included dupilumab, baracitinib; tralokinumab and upadacitinib only with early access
 - Objective of this preliminary analysis: to compare the profile of patients initiating anticytokines or JAK inhibitors for AD
 - Exclusion criteria: prescription of JAKi or anticytokine the 6 months before inclusion in the OMCCI
- 

Results

- 358 patients with moderate to severe AD


➔ 206 fulfilled the inclusion criteria

- Dupilumab n= 151
- Baricitinib n= 52
- Upadacitinib n=2
- Tralokinumab n=1

	Anticytokine (n=152)	JAKi (n=54)	P value
Mean age (years)	43.0 ± 18.6	32.0 ± 13.7	<0.001
Sex female (n,%)	77 (50.7%)	32 (59.3%)	0.277
Marital status: single (n,%)	45 (29.6%)	30 (55.6%)	0.005
Mean EASI	21.4 ± 13.7	23.4 ± 13.6	0.279
Mean DLQI	13.3 ± 6.5	11.4 ± 5.6	0.054
Hospitalisation for AD the last 6 months (n,%)	12 (7.9%)	2 (3.7%)	0.364
Mean disease duration (years)	27.6 ± 19.1	20.9 ± 14.1	0.026
Mean impact on daily life*	7.4 ± 1.9	7.3 ± 1.6	0.381
Mean impact on family life*	6.0 ± 2.8	5.3 ± 2.7	0.049
Mean impact on professional life*	6.0 ± 3.3	7.0 ± 2.4	0.171
Mean score of physical dimension of SF12	47.21 ± 9.32	51.80 ± 5.95	0.002
Mean score of mental dimensions of SF12	35.58 ± 10.64	35.58 ± 10.64	0.123

* Visual analogic scale from 0 to 10

Results

- Patients initiating anticytokine
 - greater number of body areas with extensive AD (3.5 ± 2.7 vs 2.3 ± 1.6 , $p=0.007$)
 - extensive AD lesions more frequent for thorax and abdomen, back, buttocks and thighs, legs and feet
 - Isolated head and neck involvement numerically more common in patients initiating JAKi (7.5% versus 2.6%)
 - Sick leaves due to AD the last 6 months were comparable in the 2 groups
 - JAKi initiation declined from February 2022
- 

Discussion

- Dupilumab was initiated in older patients
 - More favorable safety profile
 - More experience with this treatment
 - More data in this age group
- Revision process of JAKi's safety by health authorities had an impact on JAKi's initiation kinetics
- Portuguese recommandations:

Biologic therapy		JAK inhibitors
presence of type 2 comorbidities		need of rapid action on pruritus
hepatic or renal insufficiency		history of eye inflammation
high risk of infection or thrombo-embolic event		concurrent disease in which JAKi are indicated

Conclusion

- 2 profiles of AD patients according to the treatment choice
 - Decision seeming mostly guided by the controversial safety profile of JAKi
 - When the PRAC recommendations will be available, the validity of these choices might be questioned
- 